Anti-trypanosomal activity of (8-hydroxymethylen)-trieicosanyl acetate against infective forms of Trypanosoma cruzi

References

• Apt BW, Aguilera X, Arribada A, Pérez C, Miranda C, Sanchez G, Zulantay I, Cortés P, Rodriguez J, Juri D (1998): Treatment of chronic Chagas’ disease with itraconazole and allopurinol. Am J Trop Med Hyg 59: 133–138.
   PubMed Web of Science ®Google Scholar
• Apt W, Arribada A, Zulantay I, Solari A, Sánchez G, Mundaca K, Coronado X, Rodríguez J, Gil LC, Osuna A (2005): Itraconazole or allopurinol in the treatment of chronic American trypanosomiasis: The results of clinical and parasitological examinations 11 years post-treatment. Ann Trop Med Parasitol 99: 733–741.
   PubMed Web of Science ®Google Scholar
• Asuzu IU, Chineme CN (1990): Effects of Morinda lucida leaf extract on Trypanosoma brucei brucei infection in mice. J Ethnopharmacol 30: 307–313.
   PubMed Web of Science ®Google Scholar
• Avila JL, Avila A (1981): Trypanosoma cruzi: Effect of allopurinol in the treatment of mice with experimental acute Chagas disease. Exp Parasitol 51: 204–208.
   PubMedGoogle Scholar
• Avila JL, Avila A, Casanova J (1981): Effects of allopurinol on different strains of Trypanosoma cruzi. Am J Trop Med Hyg 39: 769–774.
   Google Scholar
• Barrera-Perez MA, Rodriguez-Felix ME, Guzman-Marin E, Zavala Velazquez J (2001): Biological behaviour of three strains of Trypanosoma cruzi from Yucatan, Mexico.Rev Biomed 12: 224–230.
   Google Scholar
• Berens RL, Marr JJ, Steele da Cruz FS, Nelson DJ (1982): Effect of allopurinol on Trypanosoma cruzi: Metabolism and biological activity in intracellular and bloodstream forms. Antimicrob Agents Chemother 22: 657–661.
   PubMed Web of Science ®Google Scholar
• Calzada F, Yépez-Mulia L, Aguilar A (2006): In vitro susceptibility of Entamoeba histolytica and Giardia lamblia to plants used in Mexican traditional medicine for the treatment of gastrointestinal disorders. J Ethnopharmacol 108: 367–370.
   PubMed Web of Science ®Google Scholar
• Castro JA, de Mecca MM, Bartel LC (2006): Toxic side effects of drugs used to treat Chagas’ disease (American trypanosomiasis). Hum Exp Toxicol 25: 471–479.
   PubMed Web of Science ®Google Scholar
• Coronado X, Zulantay I, Rozas M, Apt W, Sánchez G, Rodríguez J, Ortiz S, Solari A (2006): Dissimilar distribution of Trypanosoma cruzi clones in humans after chemotherapy with allopurinol and itraconazole. J Antimicrob Chemother 58: 216–219.
   PubMedGoogle Scholar
• Cunha WR, Crevelin EJ, Arantes GM, Crotti AE, Andrade e Silva ML, Furtado NA, Albuquerque S, Ferreira DS (2006): A study of the trypanocidal activity of triterpene acids isolated from Miconia species. Phytother Res 20: 474–478.
   PubMedGoogle Scholar
• Dantas AP, Olivieri BP, Gomes FH, De Castro SL (2006): Treatment of Trypanosoma cruzi-infected mice with propolis promotes changes in the immune response. J Ethnopharmacol 103: 187–193.
   PubMedGoogle Scholar
• Flores SJ (2001): Leguminosae, floristica, etnobotanica y ecologia. Etnoflora Yucatanense. Merida Yucatan, Mexico. Universidad Autonoma de Yucatan Press, p 157.
   Google Scholar
• Fournet A, Muñoz V (2002): Natural products as trypanocidal, antileishmanial and antimalarial drugs. Curr Top Med Chem 2: 1215–1237.
   PubMedGoogle Scholar
• Freitas HF, Chizzola PR, Paes AT, Lima AC, Mansur AJ (2005): Risk stratification in a Brazilian hospital-based cohort of 1220 outpatients with heart failure: Role of Chagas’ heart disease. Int J Cardiol 102: 239–247.
   PubMed Web of Science ®Google Scholar
• Guzman E, González R, Flores S, Zavala J, Rosado M, Pérez S (2004): Activity of Senna villosa against Trypanosoma cruzi. Pharm Biol 42: 504–507.
   Google Scholar
• Guzman E, Perez C, Zavala MA, Acosta-Viana KY, Perez S (2008): Antiprotozoal activity of (8-hydroxymethylen)-trieicosanyl acetate isolated from Senna villosa. Phytomedicine 15: 892–895.
   PubMedGoogle Scholar
• Higuchi ML, De Morais CF, Pereira Barreto AC, Lopes EA, Stolf N, Bellotti G, Pileggi F (1987): The role of active myocarditis in the development of heart failure in chronic Chagas’ disease: A study based on endomyocardial biopsies. Clin Cardiol 10: 665–670.
   PubMed Web of Science ®Google Scholar
• Horiuchi H, Ota M, Nishimura S, Kaneko H, Kasahara Y, Ohta T, Komoriya K (2000): Allopurinol induces renal toxicity by impairing pyrimidine metabolism in mice. Life Sci 66: 2051–2070.
   PubMed Web of Science ®Google Scholar
• Lira R, Contreras LM, Rita RM, Urbina JA (2001): Mechanism of action of anti-proliferative lysophospholipid analogues against the protozoan parasite Trypanosoma cruzi: Potentiation of in vitro activity by the sterol biosynthesis inhibitor ketoconazole. J Antimicrob Chemother 47: 537–546.
   PubMed Web of Science ®Google Scholar
• Marin-Neto JA, Cunha-Neto E, Maciel BC, Simões MV (2007): Pathogenesis of chronic Chagas heart disease. Circulation 115: 1109–1123.
   PubMed Web of Science ®Google Scholar
• Mena JG, Pech SG, Brito L (1997): Anthraquinones from Senna villosa Mill. Rev Latinoamer Quim 25: 128–131.
   Google Scholar
• Milei J, Guerri-Guttenberg RA, Grana DR, Storino R (2009): Prognostic impact of Chagas disease in the United States. Am Heart J 157: 22–29.
   PubMed Web of Science ®Google Scholar
• Nakajima-Shimada J, Hirota Y, Aoki T (1996): Inhibition of Trypanosoma cruzi growth in mammalian cells by purine and pyrimidine analogs. Antimicrob Agents Chemother 40: 2455–2458.
   PubMed Web of Science ®Google Scholar
• OECD (2001): Acute oral toxicity: Up-and-down procedure (updated guideline, adopted 20th December 2001), available at:www.epa.gov/oppfead1/harmonization/docs/E425guideline.pdf (accessed December 31, 2008).
   Google Scholar
• Paulino M, Iribarne F, Dubin M, Aguilera-Morales S, Tapia O, Stoppani AO (2005): The chemotherapy of Chagas’ disease: An overview. Mini Rev Med Chem 5: 499–519.
   PubMed Web of Science ®Google Scholar
• Santa-Rita RM, Lira R, Barbosa HS, Urbina JA, de Castro SL (2005): Anti-proliferative synergy of lysophospholipid analogues and ketoconazole against Trypanosoma cruzi (Kinetoplastida: Trypanosomatidae): Cellular and ultrastructural analysis. J Antimicrob Chemother 55: 780–784.
   PubMed Web of Science ®Google Scholar
• Schmeda-Hirshmann G, Astudillo L, Bastida J, Codina C, Rojas de Arias A, Ferreira ME, Inchausti A, Yaluff G, (2001): Cryptofolione derivatives from Cryptocarya alba fruits. J Pharm Pharmacol 53: 563–567.
   PubMedGoogle Scholar
• Tarleton RL, Reithinger R, Urbina JA, Kitron U, Gürtler RE (2007): The challenges of Chagas disease- grim outlook or glimmer of hope. PLoS Med 4: e33.
   Google Scholar
• Urbina J (1999): Parasitological cure of Chagas disease: Is it possible? Is it relevant? Mem Inst Oswaldo Cruz 94:349–355.
   PubMed Web of Science ®Google Scholar
• WHO (2007): Reporte sobre la enfermedad de Chagas. Training in tropical disease (TDR). TDR/SWG/09, Geneva Switzerland. World Health Organization.
   Google Scholar